These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37924016)

  • 1. Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis.
    Gao X; Zeng H; Zhao X; Wu H; Yan M; Li Y; Zhang G; Sun F
    BMC Cancer; 2023 Nov; 23(1):1058. PubMed ID: 37924016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.
    Moreau P; Chanan-Khan A; Roberts AW; Agarwal AB; Facon T; Kumar S; Touzeau C; Punnoose EA; Cordero J; Munasinghe W; Jia J; Salem AH; Freise KJ; Leverson JD; Enschede SH; Ross JA; Maciag PC; Verdugo M; Harrison SJ
    Blood; 2017 Nov; 130(22):2392-2400. PubMed ID: 28847998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
    He W; He F; Hu H
    Ann Med; 2023 Dec; 55(1):1029-1036. PubMed ID: 36911885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.
    Kumar S; Kaufman JL; Gasparetto C; Mikhael J; Vij R; Pegourie B; Benboubker L; Facon T; Amiot M; Moreau P; Punnoose EA; Alzate S; Dunbar M; Xu T; Agarwal SK; Enschede SH; Leverson JD; Ross JA; Maciag PC; Verdugo M; Touzeau C
    Blood; 2017 Nov; 130(22):2401-2409. PubMed ID: 29018077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
    Badawi M; Coppola S; Eckert D; Gopalakrishnan S; Engelhardt B; Doelger E; Huang W; Dobkowska E; Kumar S; Menon RM; Salem AH
    Hematol Oncol; 2024 Jan; 42(1):e3222. PubMed ID: 37740931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma.
    Gasparetto C; Bowles KM; Abdallah AO; Morris L; Mander G; Coppola S; Wang J; Ross JA; Bueno OF; Arriola E; Mateos MV
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):775-784. PubMed ID: 34551886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of venetoclax in t(11;14) positive relapsed/refractory multiple myeloma: A systematic review.
    Khan WJ; Ali M; Hashim S; Nawaz H; Hashim SN; Safi D; Inayat A
    J Oncol Pharm Pract; 2024 Apr; 30(3):552-561. PubMed ID: 38113108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.
    Regidor B; Goldwater MS; Wang J; Bujarski S; Swift R; Eades B; Emamy-Sadr M; Eshagian S; Schwartz G; Spektor TM; Berenson JR
    Ann Hematol; 2021 Aug; 100(8):2061-2070. PubMed ID: 33987683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
    Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa LJ; Davies FE; Monohan GP; Kovacsovics T; Burwick N; Jakubowiak A; Kaufman JL; Hong WJ; Dail M; Salem AH; Yang X; Masud AA; Munasinghe W; Ross JA; Bueno OF; Kumar SK; Stadtmauer EA
    Blood Adv; 2021 Oct; 5(19):3748-3759. PubMed ID: 34470049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma.
    Kambhampati S; Galligan D; Huang CY; Wong S; Wolf J; Martin T; Shah N
    Leuk Lymphoma; 2020 May; 61(5):1211-1219. PubMed ID: 31928108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis.
    Xu L; Lin S; Xing X; Su Y
    Ther Adv Hematol; 2023; 14():20406207231155028. PubMed ID: 36895915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-CD38 monoclonal antibodies in patients with relapsed/refractory multiple myeloma: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Ye L; Zhou F; Cheng D; Xie M; Yan X; Xue Y; Yang Q; Jia R; Zhong L; Yang L; Zou L; Huang N
    Front Oncol; 2023; 13():1240318. PubMed ID: 38144527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
    Wang X; Zhao A; Zhu J; Niu T
    Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects.
    AlZahrani A; Alsuhebany N; Tailor IK; Alrajhi AM
    Hematology; 2024 Dec; 29(1):2296809. PubMed ID: 38149670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
    Freise KJ; Jones AK; Verdugo ME; Menon RM; Maciag PC; Salem AH
    Clin Pharmacol Ther; 2017 Dec; 102(6):970-976. PubMed ID: 28419431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
    Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
    Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
    Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.